MAIA Biotechnology Aktie [WKN DE: A3DGQQ / ISIN: US5526411021]

Kurse + Charts + Realtime		News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (groß)	News + Adhoc	Bilanz/GuV	Termine	Zertifikate	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil	Optionsscheine	Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV	Knock-Outs
Historisch	Analysen

Kurse + Charts + Realtime
Kurs + Chart
Times + Sales
Börsenplätze
Historisch

News + Analysen
News + Adhoc
Analysen
Kursziele

Fundamental
Bilanz/GuV
Schätzungen
Dividende/GV
Analysen

Unternehmen
Termine
Profil

zugeh. Wertpapiere
Zertifikate
Optionsscheine
Knock-Outs

Nachrichten zu MAIA Biotechnology Inc Registered Shs

07.11.24		MAIA Biotechnology Announces Participation by Director Stan Smith, Ph.D. in Recent Private Placement (Businesswire)
05.11.24		MAIA Biotechnology Announces Late-Breaking Abstract of THIO-101 Updates Selected for Oral and Poster Presentation at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting (Businesswire)
29.10.24		MAIA Biotechnology Announces $2.44 Million Private Placement (Businesswire)
15.10.24		MAIA Biotechnology Announces Poster Presentation of Novel THIO Prodrugs at ENA 2024 Symposium on Molecular Targets and Cancer Therapeutics (Businesswire)
10.09.24		MAIA Biotechnology Announces Positive Survival Updates in Phase 2 Study of THIO in Non-Small Cell Lung Cancer (Businesswire)
04.09.24		MAIA Biotechnology to Present New Phase 2 Clinical Trial Data at the H.C. Wainwright 26th Annual Global Investment Conference (Businesswire)
23.07.24		MAIA Biotech Reports Positive Phase 2 Data For THIO With Cemiplimab In Non-Small Cell Lung Cancer (RTTNews)
23.07.24		MAIA Biotechnology Announces New Updates from Phase 2 Trial of Novel Cancer Treatment Agent (Businesswire)
07.06.24		MAIA Biotechnology's Telomere Targeting Functionality is Shown Viable by FDA’s Approval of a Telomerase Inhibitor Agent Therapy (Businesswire)
06.06.24		MAIA Biotechnology Announces Year-to-Date Achievements and Highlights Recent Clinical Progress for Novel Anticancer Agent (Businesswire)
04.06.24		MAIA Biotech's Phase 2 THIO-101 Study Shows Positive Results In Non-Small Cell Lung Cancer (RTTNews)
04.06.24		MAIA Biotechnology Reveals New Clinical Data Showing THIO’s Strong Efficacy in Non-Small Cell Lung Cancer (Businesswire)
17.05.24		MAIA Biotechnology to Present at the BIO International Convention 2024 (Businesswire)
16.05.24		MAIA Biotechnology Abstract Accepted for Poster Presentation at American Society of Clinical Oncology (ASCO) 2024 Annual Meeting (Businesswire)
30.04.24		MAIA Biotechnology Announces Share Purchase by Director Adelina Louie in Private Placement (Businesswire)
29.04.24		MAIA Biotechnology Announces Share Purchase by Director Stan Smith, Ph.D. in Private Placement (Businesswire)
23.04.24		MAIA Biotechnology Announces $1.00 Million Private Placement (Businesswire)
05.04.24		MAIA Biotechnology to Present at Two Investor Conferences in April 2024 (Businesswire)
28.03.24		MAIA Biotechnology Announces Share Purchases by Directors Cristian Luput and Ramiro Guerrero (Businesswire)
26.03.24		MAIA Biotechnology Announces Share Purchase by Director Adelina Louie in Private Placement (Businesswire)
26.03.24		MAIA Biotechnology Announces $1.33 Million Private Placement (Businesswire)
22.03.24		MAIA Biotechnology Announces Share Purchase by Director Stan Smith, PhD in a $2.9 Million Private Placement (Businesswire)
21.03.24		MAIA Biotechnology Welcomes Prominent Medical Oncology Scientist Dr. Saadettin Kilickap to its Scientific Advisory Board (Businesswire)
07.03.24		MAIA Biotechnology to Participate in the 36th Annual ROTH Conference (Businesswire)
06.03.24		MAIA Biotechnology and Nationwide Children’s Hospital Announce Presentation of THIO’s Potency in Pediatric Brain Tumors at American Association of Cancer Research Annual Meeting (Businesswire)
06.03.24		MAIA Announces Positive Data From Phase 2 THIO Clinical Trial For NSCLC; Stock Rises 8% (RTTNews)
06.03.24		MAIA Biotechnology Announces Strong Efficacy of THIO as Third-Line Treatment for Non-Small Cell Lung Cancer Patients (Businesswire)
05.03.24		MAIA Biotechnology CEO Details Immuno-Oncology Cancer Treatment Candidates and Development Pipeline in Letter to Shareholders (Businesswire)
07.02.24		MAIA Biotechnology Announces Publication in Nature Communications on Positive Effects of THIO for Potential Treatment of Small Cell Lung Cancer (Businesswire)
24.01.24		MAIA Biotechnology Announces Publication of International PCT Patent Application Covering Anticancer Telomere-Targeting Compounds (Businesswire)
17.01.24		MAIA Biotechnology Provides Positive Phase 2 Clinical Updates for Lead Anticancer Agent and Outlines Targeted Milestones for 2024 (Businesswire)
05.01.24		MAIA Biotechnology to Present at Biotech Showcase 2024 on January 9, 2024 (Businesswire)
19.12.23		MAIA Biotechnology Announces Dose Selection in THIO-101 Phase 2 Clinical Trial for Non-Small Cell Lung Cancer (Businesswire)
17.11.23		MAIA Biotechnology Announces Closing of $4 Million Registered Direct Offering (Businesswire)
15.11.23		MAIA Biotechnology Announces $4 Million Registered Direct Offering (Businesswire)
10.11.23		Orphan Drug Status For MAIA Biotechnology's THIO To Treat Glioblastoma (RTTNews)
10.11.23		FDA Grants Orphan Drug Designation to MAIA Biotechnology for THIO as a Treatment for Glioblastoma (Businesswire)
07.11.23		MAIA Biotechnology Reports Third Quarter 2023 Financial Results and Highlights Recent Development Progress for Anticancer Asset THIO (Businesswire)
30.10.23		MAIA Biotechnology Reveals Higher Anticancer Potency of Telomere-Targeting Compounds Derived from THIO (Businesswire)
24.10.23		MAIA Biotechnology Announces 100% Disease Control in Second-Line Non-Small Cell Lung Cancer Demonstrating Impressive Positive Preliminary Efficacy Data for Ongoing THIO-101 Phase 2 Trial (Businesswire)
19.10.23		MAIA Biotechnology to Present Preliminary Safety and Efficacy Data from THIO-101 Phase 2 Clinical Trial at European Society for Medical Oncology Congress 2023 (Businesswire)
17.10.23		MAIA Biotechnology to Present Latest Findings for Second Generation THIO Program at Turkish Biochemical Society’s International Biochemistry Congress 2023 (Businesswire)
12.10.23		Pre-market Movers: OPGN, TPST, FAT, MAIA, TUP… (RTTNews)
10.10.23		MAIA Biotechnology Accelerates Enrollment in THIO-101 Phase II Clinical Trial as Efficacy Is Observed in Dosed Patients (Businesswire)
10.10.23		MAIA Biotechnology Announces Potent Anticancer Activity of THIO in Gliomas (Businesswire)
03.10.23		MAIA Biotechnology Obtains FDA Clearance To Extend Go-to-market THIO-101 Trial To The U.S. (RTTNews)
03.10.23		MAIA Biotechnology Announces FDA Clearance of IND Application for THIO, a First-in-Class Telomere Targeting Agent for the Treatment of Non-Small Cell Lung Cancer (Businesswire)
28.09.23		MAIA Biotechnology To Repurchase Up To $800K Of Shares (RTTNews)
28.09.23		MAIA Biotechnology Announces Share Repurchase Program (Businesswire)
08.08.23		MAIA Biotechnology Reports Second Quarter 2023 Financial Results and Provides Updates for THIO-101 Phase 2 Trial for Non-Small Cell Lung Cancer (Businesswire)

1 | Weiter

Newssuche

Meistgelesene Nachrichten

Drohende Korrektur? Experte schlägt Alarm bei der NVIDIA-Aktie

Neuer Rekord nicht mehr weit: Bitcoin, Ethereum, Litecoin & Co.: Wie sich die Kryptokurse am Mittag entwickeln

Pierer Mobility-Aktie zweistellig im Plus: Pierer dementiert Mateschitz-Einstieg bei KTM

UN-Klimagipfel in Baku: Baerbock warnt vor 'Killerstürmen'

Angespannte Stimmung in Frankfurt: LUS-DAX gibt am Nachmittag nach

Nah an 100.000er Marke: Bitcoin, Dogecoin, Ethereum & Co. am Vormittag

finanzen.net Apps

ETF-Sparplan

Oskar ist der einfache und intelligente ETF-Sparplan. Er übernimmt die ETF-Auswahl, ist steuersmart, transparent und kostengünstig.

JETZT MEHR ERFAHREN

Aktien ATX DAX EuroStoxx 50 Dow Jones NASDAQ 100 Nikkei 225 S&P 500

Kontakt - Impressum - Werbung

Sitemap - Datenschutz - Disclaimer - AGB - Privatsphäre-Einstellungen

Für die aufgeführten Inhalte kann keine Gewährleistung für die Vollständigkeit, Richtigkeit und Genauigkeit übernommen werden.
Kursinformationen von SIX Financial Information Deutschland GmbH. Verzögerung 15 Min. (Nasdaq, NYSE: 20 Min.).
© 1999-2024 finanzen.net GmbH

*Werbehinweise: Die Billigung des Basisprospekts durch die Bundesanstalt für Finanzdienstleistungsaufsicht ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.

⁵Hinweis zu Plus500: 82% der Kleinanlegerkonten verlieren Geld beim CFD-Handel mit diesem Anbieter. Sie sollten überlegen, ob Sie es sich leisten können, das hohe Risiko einzugehen, Ihr Geld zu verlieren. Plus500UK Ltd ist zugelassen und reguliert durch Financial Conduct Authority (FRN 509909). Plus500CY Ltd authorized & regulated by CySEC (#250/14).

Währungsrechner News Devisen Dollarkurs Aktienkurse Bitcoin Rohstoffe Fonds

Portfolioname: Watchlistname:
Portfolio:
Name:
Typ:
ISIN:
Börse:
Anzahl:
Aktueller Kurs:
Kurszeit:
Kaufpreis:
Kaufdatum:	26.11.2024 23:20
Kaufwert:	EUR
	Hinzufügen Speichern